The Tumor Immunology (Tl) Program Area brings basic and translational scientists together into an environment that has spawned novel, investigator-initiated immunotherapy clinical trials for melanoma, brain cancers, lymphomas, lung cancer and renal cell carcinoma, among others. The main goals of the Program Area are: 1) to provide an optimal interactive environment to enhance the understanding of tumor immunology, and 2) to develop novel immune-based clinical therapies for patients with cancer. Established intra- and inter-programmatic research areas include: 1) T cell receptor engineering for adoptive cell transfer therapy;2) new platforms for immune monitoring of T cell responses to cancer;3) non-invasive in vivo imaging of tumor antigen-specific T cells;4) immunotherapy for brain cancers;5) the relationship between inflammation and cancer;and 6) the use of antibody fusion proteins, immune-modulating antibodies and chemokines for cancer therapy. The Tl Program Area also houses research efforts both on gene therapy approaches to cancer treatment and on viral oncogenesis, including studies of HIV/AIDS. The Tl Program Area uses nearly all of the JCCC-supported infrastructure and shared resources. The Flow Cytometry Shared Resource is a key facility required for most (if not all) research projects within the Program Area. The Small Animal Imaging Shared Resource has made possible the pursuit of successful projects in T cell imaging, projects that are now being brought from preclinical models to patients. The JCCC/Human Gene Medicine Program Good Manufacturing Practices (GMP) suite has provided the required physical infrastructure for investigators in the Tl Program Area to manufacture cell and gene therapy products in-house, meeting all of the local, state and federal regulatory requirements for human administration. The Tl Program Area is comprised of 37 members, including six

Public Health Relevance

The treatment of cancer by promoting an anti-tumor immune response offers great promise for the future. The Tumor Immunology Program Area brings together basic, translational, and clinical researchers from multiple disciplines to realize this promise. A broad range of therapeutic strategies for enhancing the antitumor immune response are being pursued, with important intra- and inter-programmatic collaborations to test and monitor the success of each strategy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016042-39
Application #
8635434
Study Section
Subcommittee G - Education (NCI)
Project Start
1996-12-01
Project End
2018-11-30
Budget Start
2014-03-07
Budget End
2014-11-30
Support Year
39
Fiscal Year
2014
Total Cost
$28,121
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Wu, Sheng; Wong, Weng Kee; Crespi, Catherine M (2017) Maximin optimal designs for cluster randomized trials. Biometrics 73:916-926
Douaisi, Marc; Resop, Rachel S; Nagasawa, Maho et al. (2017) CD31, a Valuable Marker to Identify Early and Late Stages of T Cell Differentiation in the Human Thymus. J Immunol 198:2310-2319
Qi, Hangfei; Chu, Virginia; Wu, Nicholas C et al. (2017) Systematic identification of anti-interferon function on hepatitis C virus genome reveals p7 as an immune evasion protein. Proc Natl Acad Sci U S A 114:2018-2023
Lu, Jianqin; Liu, Xiangsheng; Liao, Yu-Pei et al. (2017) Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression. Nat Commun 8:1811
Castaneda, Julie T; Harui, Airi; Roth, Michael D (2017) Regulation of Cell Surface CB2 Receptor during Human B Cell Activation and Differentiation. J Neuroimmune Pharmacol 12:544-554
Casillas, Jacqueline; Goyal, Anju; Bryman, Jason et al. (2017) Development of a text messaging system to improve receipt of survivorship care in adolescent and young adult survivors of childhood cancer. J Cancer Surviv 11:505-516
Su, Yapeng; Wei, Wei; Robert, Lidia et al. (2017) Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance. Proc Natl Acad Sci U S A 114:13679-13684
Demer, Linda L; Tintut, Yin; Nguyen, Kim-Lien et al. (2017) Rigor and Reproducibility in Analysis of Vascular Calcification. Circ Res 120:1240-1242
Kiyohara, M H; Dillard, C; Tsui, J et al. (2017) EMP2 is a novel therapeutic target for endometrial cancer stem cells. Oncogene 36:5793-5807
Dock, Jeffrey; Ramirez, Christina M; Hultin, Lance et al. (2017) Distinct aging profiles of CD8+ T cells in blood versus gastrointestinal mucosal compartments. PLoS One 12:e0182498

Showing the most recent 10 out of 721 publications